4 results
To evaluate LFS after allo HCT in AML/RAEB in complete remission using matched or unrelated donors in comparison to conventional chemotherapy
1.3. Study Design Rationale The ATLAS-PPX trial (ALN-AT3SC-009) is a multicenter, multinational, open-label Phase 3 switching study designed to demonstrate the efficacy and safety of fitusiran in patients with hemophilia A or B, with inhibitory…
1.3. Study Design Rationale The ATLAS-INH trial (ALN-AT3SC-003) is a multicenter, multinational, randomized, openlabel Phase 3 study designed to demonstrate the efficacy and safety of fitusiran in patients with haemophilia A or B with inhibitory…
PRIMARY OBJECTIVE:To assess the safety and tolerability of MOR202 treatment in subjects with aMNKEY SECONDARY OBJECTIVE:To assess the effect of MOR202 on serum anti-PLA2R antibodies in subjects with aMNSECONDARY OBJECTIVES:1. To assess…